View Older Stories View More Recent Stories
-
Vertex secures Italian reimbursement deal for gene therapy CASGEVY
-
Goldman Sachs Reiterates Buy Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $34 at BofA Securities
-
Vertex (VRTX) PT Lowered to $411 at Canaccord Genuity
-
Vertex (VRTX) PT Lowered to $405 at RBC Capital Amid Setbacks
-
Vertex (VRTX) PT Lowered to $530 at BMO Capital
-
Vertex (VRTX) PT Lowered to $455 at Stifel
-
Vertex (VRTX) PT Raised to $471 at Bernstein SocGen Group
-
Vertex (VRTX) PT Lowered to $485 at Cantor Fitzgerald
-
Vertex (VRTX) PT Lowered to $490 at Truist Securities
-
Vertex (VRTX) PT Lowered to $478 at H.C. Wainwright
-
Vertex (VRTX) PT Lowered to $458 at Leerink Partners
-
Vertex (VRTX) PT Lowered to $553 at UBS
-
After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more
-
Vertex Pharma (VRTX) Tops Q2 EPS by 25c, Beats on Revenue; Offers FY25 Revenue Guidance
-
Vertex Pharma (VRTX) call put ratio 1.4 calls to 1 put into quarter results
-
Vertex Pharma (VRTX) call put ratio 1 call to 1.3 puts into quarter results
-
Vertex (VRTX) PT Lowered to $38 at BMO Capital
-
Vertex Pharma (VRTX) receives marketing authorization in Canada for Alyftrek
-
U.S. large biotech stocks Q2 earnings preview
-
Vertex Pharma (VRTX) Announces European Commission Approval of ALYFTREK
-
William Blair Reiterates Outperform Rating on Vertex (VRTX)
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $420 at RBC Capital
-
Vertex Pharma (VRTX) reveals new data on ALYFTREK
-
RBC Capital weighs in on Vertex (VRTX) following IgAN competitor data
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel on Sionna Therapeutics (SION): 'both compounds are able to attain exposures well above the modeled PK threshold'
-
BofA Securities Reiterates Buy Rating on Vertex (VRTX)
-
BMO Capital Reiterates Outperform Rating on Vertex (VRTX)
-
UBS Reiterates Buy Rating on Vertex (VRTX) after positive doc call on Journavx uptake
-
Erste Group Downgrades Vertex (VRTX) to Hold, 'The ratio of receivables to sales is also at a very high level'
-
Scotiabank Reiterates Sector Perform Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Approves Additional $4B Buyback Program
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Bernstein on Vertex (VRTX): 'We'd Sit Tght' Following Yesterday's Stock Sell-Off
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Wolfe Research Downgrades Vertex (VRTX) to Peerperform
-
Vertex (VRTX) PT Raised to $462 at Bernstein SocGen Group
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $442 at Scotiabank
-
Leerink Partners Downgrades Vertex (VRTX) to Market Perform 'on Lower Pain Projections'
-
After-hours movers: Palantir, Ford, Clorox and more
-
Vertex Pharma (VRTX) Misses Q1 EPS by 20c; raises guidance
-
Vertex Pharma (VRTX) call put ratio 1.2 calls to 1 put into quarter results
-
Vertex Pharma (VRTX) call put ratio 5.8 calls to 1 put into quarter results
-
UBS Reiterates Buy Rating on Vertex (VRTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Cantor Fitzgerald Assumes Vertex (VRTX) at Overweight

